In addition, the significant prognostic role of the peptide is supported by the fact that with an increasing depth of therapeutic response, the PACAP levels of MM patients will rise until reaching the plasma values of healthy subjects. The gene discussed is ADCYAP1; the disease is Miyoshi myopathy.